1 Min Read
March 6 (Reuters) - Crossject SA:
* Gets authorization to conduct study on bioequivalence of Zeneo Midazolam Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.